key: cord-0710170-4hzl4pq2
authors: Wang, Jing; Wang, Yanling; Wang, Tao; Xing, Xiaokang; Zhang, Ge
title: Is Extracorporeal Membrane Oxygenation the Standard Care for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis
date: 2020-11-04
journal: Heart Lung Circ
DOI: 10.1016/j.hlc.2020.10.014
sha: 6e05b8f7bef1ad3ac58d794924f002a0db52d25b
doc_id: 710170
cord_uid: 4hzl4pq2

BACKGROUND: Acute respiratory distress syndrome (ARDS) is a type of acute respiratory failure syndrome characterised by severe respiratory distress and stubborn hypoxaemia. Patients with ARDS have a prolonged hospital stay and high mortality rate. Over long-term follow-up, ARDS is found to be associated with a high incidence of long-term complications and decreased quality of life. Venovenous extracorporeal membrane oxygenation (vv-ECMO) has been widely used for the treatment of refractory ARDS. However, it is not the standard treatment as recommended by ARDS guidelines. AIM: The aim of this study was to compare the effects of ECMO (vv-ECMO) and conventional mechanical ventilation (CMV) on the clinical outcomes in patients with ARDS. METHOD: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, Medline, EMBASE, Web of Science, and PubMed databases up to November 2019. We selected appropriate studies according to our inclusion and exclusion criteria, and extracted and analysed the data using RevMan 5.0 software to evaluate the effectiveness of ECMO systematically. RESULTS: A total of 18 articles and 2,399 patients were included in this meta-analysis: 898 patients in the ECMO group and 1,501 patients in the CMV group. Treatment with ECMO may be associated with reduced 1-year mortality (95% confidence interval [CI], 0.27–0.83; p=0.009) and 60-day mortality (95% CI, 0.37–0.86; p=0.008), but increased Intensive Care Unit mortality (95% CI, 1.26–2.36; p=0.0007) of patients with ARDS. Extracorporeal membrane oxygenation may not be related to 30-day mortality or complications such as nosocomial pneumonia, haemorrhagic stroke, or continuous renal replacement therapy in patients with ARDS. However, some results showed heterogeneity, such as bleeding complications and in-hospital mortality. Subgroup analysis showed that ECMO treatment might increase ICU mortality (p=0.002) and nosocomial pneumonia complications (p=0.03) in patients with H1N1 ARDS. CONCLUSIONS: Compared with CMV, ECMO contributed to lower 60-day and 1-year mortality, and increased ICU mortality in patients with ARDS. However, H1N1 ARDS was independently associated with higher ICU mortality and nosocomial pneumonia. The results were not affected by removing retrospective control studies or articles published >20 years ago from the sensitivity analysis. This meta-analysis demonstrates the effectiveness of ECMO and its importance in standard treatment of patients with ARDS.

First discovered in 1967 [1] , acute respiratory distress syndrome (ARDS) is a unique type of hypoxaemic respiratory failure characterised by the acute onset of hypoxaemia and diffuse alveolar damage caused by non-cardiogenic pulmonary oedema. Without timely intervention, ARDS can evolve into to multi-organ failure. Therefore, it should not be underestimated.

Acute respiratory distress syndrome is a multifactorial lung injury. At present, there is no clear understanding of its epidemiology and outcome. Several studies have indicated that the most common risk factors for ARDS include pneumonia and non-pulmonary sepsis [2] [3] [4] . Other susceptibility factors include smoking, alcohol, drugs, heavy blood transfusions, obesity, and genetic factors.

A prospective, multicentre study found that the morbidity and mortality of ARDS increased with age, and that the inhospital mortality rate was 41.1% [5] . In the USA, there are an estimated 190,000 cases, 74,000 deaths, and 3.6 million hospital days annually. Another large observational study, Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) [6] , included 29,144 patients from 459 intensive care units (ICUs) in 50 countries; 3,022 (10.4%) of whom met the ARDS criteria over 4 weeks. Mortality increased with the severity of ARDS. For patients with mild, moderate, and severe ARDS, hospital mortality rates were 34.9%, 40.3%, and 46.1%, respectively.

A small number of patients with ARDS die from respiratory failure, while most die from their primary illness or secondary complications, such as sepsis and multiple organ dysfunction syndrome. Muscle weakness after ICU discharge is a frequent complication of ARDS and usually recovers within 12 months [7] . Any serious physical injury and decreased quality of life associated with muscle weakness lasts for .24 months.

At present, there are several treatment options for ARDS. Lung protective ventilation with low tidal volume, limited plateau pressure, and prone positioning are strongly recommended treatment options for ARDS, as per 2018 guidelines [8] . High-frequency oscillatory ventilation has no advantages over conventional mechanical ventilation (CMV), and may result in higher mortality [9] . For many years, extracorporeal membrane oxygenation (ECMO) remained a weak recommendation for ARDS owing to its significant complications and the lack of high-quality clinical research data.

Extracorporeal membrane oxygenation can improve oxygenation and remove carbon dioxide, and then reduce ventilator support (low tidal volume and low airway pressure, etc.), to rest the lungs and maintain a protective ventilation strategy of open lungs in order to buy time for treatment of the original disease [10] .

In recent years, with the continuous progress in technology, ECMO has progressively achieved better clinical results in ARDS. The Conventional ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) study [11] , a UK-based multicentre trial, recommend that patients with serious and recoverable ARDS should be sent to hospitals with ECMO availability. Extracorporeal membrane oxygenation did not only increase the survival rate, but also the quality-adjusted life-years in ARDS without disability. However, the ECMO to Rescue Lung Injury in Severe ARDS (EOLIA) study [12] , a recent international randomised controlled trial (RCT), found that 60-day mortality in the ECMO group was not significantly lower compared with the CMV group.

This meta-analysis combined previously published highquality clinical research, with an evaluation of whether ECMO should be the standard care in ARDS.

The inclusion criteria were based on the PICOS acronym (participant, intervention, comparison, outcomes of interest, and study design). Included patients with ARDS were identified according to ARDS criteria [1, [13] [14] [15] , which were defined when the articles were published. Meaningful outcomes for patients with ARDS treated with venovenous (vv)-ECMO included mortality and the associated incidence of complications, such as 30-day mortality, 60-day mortality, 1-year mortality, ICU mortality, in-hospital mortality, and nosocomial pneumonia, haemorrhagic stroke, bleeding, and the need for continuous renal replacement therapy (CRRT).

The exclusion criteria were clear: patients without ARDS, those ,18 years of age, pregnancy, treatment with venoarterial ECMO, had none of the abovementioned outcomes, animal studies, and non-control studies.

We searched RCTs and retrospective control studies (RCS) for the use of ECMO in ARDS in the following databases, up to 24 November 2019: the Cochrane Library, EMBASE, PubMed, Medline, Web of Science, and CNKI (China National Knowledge Infrastructure). The medical subject heading terms and EMTREE keywords included "extracorporeal membrane oxygenation", "Oxygenation, Extracorporeal Membrane", "Membrane Oxygenation, Extracorporeal", "Extracorporeal Life Support", "Life Support, Extracorporeal", "Support, Extracorporeal Life", "ECLS", "ECMO", "Acute respiratory failure", "Adult Respiratory Distress Syndrome", "Acute Respiratory Distress Syndrome", and "ARDS".

The scope of this screening article was huge, and the process of article inclusion and exclusion is shown in Figure 1 .

Two independent investigators were responsible for extracting articles and related data based on the inclusion/ exclusion criteria. The disagreements were solved by consultation with the corresponding author (G.Z.). In addition, we tried to contact the original authors by email for incomplete data but received no response.

The risk of bias of the screened RCTs was evaluated by RevMan version 5.3 (Cochrane Collaboration, Copenhagen, Denmark). The quality of non-RCTs was assessed with the Newcastle-Ottawa Scale. Data processing of the metaanalysis of was done with RevMan 5.3.

A total of 2,570 articles that described the effects of ECMO in ARDS were retrieved. After screening, four RCTs and 14 RCSs were included in the meta-analysis. However, two of the RCTs were published .20 years ago. The study group included 898 patients with ARDS treated with ECMO and 1,501 patients with ARDS treated with CMV (control group).

The baseline characteristics of the included studies are given in Table 1 [11, 12, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Next, we extracted data from the 18 studies and analysed the correlation between ECMO therapy and outcomes in patients with ARDS.

Three (3) articles (80 patients) reported 30-day mortality. As can be seen in Figure 2 , ECMO may not be related to 30 

As can be seen in Figure 3 , ECMO may be associated with decreased 60-day mortality in ARDS (OR, 0.57; 95% CI, 0.37-0.86 [z=2.65; p=0.008; c 2 =2.39; p for heterogeneity=0.3; I 2 =16%]). Subgroup analyses showed that even if the article from 1979 was excluded, the result remained the same (p=0.007).

As is shown in Figure 4 , ECMO in ARDS may be associated with higher ICU mortality (OR, 1.72; 95% CI, 1.26-2.36 [z=3.37; p=0.0007; c 2 =26.46; p for heterogeneity ,0.0001; I 2 =81%]).

Next, the therapeutic effect of ECMO in ARDS caused by H1N1 (H1N1-ARDS) in the pneumonia subgroup was analysed. Subgroup analyses found that ECMO treatment might worsen ICU mortality in the H1N1-ARDS subgroup (p=0.002; I 2 =80%). However, the I 2 suggested significant heterogeneity among the studies. Sensitivity analyses was carried out, and the results showed that, after removing the study by Pham et al. [26] , the I 2 of the ECMO study group with H1NI ARDS was 0. The I 2 of the whole ECMO study group was 0 after the removal of the studies by Munoz et al. [30] and Pham et al. [26] . Moreover, the results did not change, suggesting they were reliable. Figure 5 shows that the effect of ECMO in ARDS might not be associated with in-hospital mortality (OR, 1.06; 95% CI, 0.81-1.38 [z=0.42; p=0.67; c 2 =49.90; p for heterogeneity ,0.00001; I 2 =84%]). Subgroup analysis showed that ECMO was not associated with in-hospital mortality of the H1N1-ARDS subgroup (p=0.90; I 2 =91%).

The I 2 value suggested significant heterogeneity among the studies. We did not find a suitable solution to the heterogeneity. Therefore, this result might not be reliable. 

The results shown in Figure 7 did not indicate a relation between ECMO and nosocomial pneumonia (OR, 1.21; 95% CI, 0.82-1.78 [z=0.94; p=0.35; c 2 =0.10; p for heterogene-ity=0.75; I 2 =54%]). The I 2 indicated moderate heterogeneity among the studies. However, ECMO might be related to the increase in nosocomial pneumonia seen in the H1N1-ARDS patient subgroup (p=0.03; I 2 =0%).

As shown in Figure 8 

As shown in Figure 9 , ECMO may not be associated with haemorrhagic stroke ( 

Extracorporeal membrane oxygenation was also not associated with the incidence of the CRRT (OR, [17] , and to 25% (SOFA) after removing the studies by Mi et al. [12] and Noah et al. [31] . The p-value remained ,0.05, indicating that the APACHE II and SOFA scores were associated with ECMO treatment.

In this meta-analysis, we found that ECMO treatment might increase the ICU mortality of and the incidence of nosocomial pneumonia in patients with H1N1-ARDS. However, there has been no previous high-quality conclusion about ICU mortality. Some possibilities may account for this finding. Firstly, previous studies compared patients with H1N1 ARDS and non-H1N1 ARDS and found that patients with H1N1 ARDS had a more rapidly extensive viral pneumonia with severe lung function impairment, higher body mass indexes (BMIs), higher ICU resource consumption, required ECMO support more often, and needed longer ECMO support times and longer ICU stays [26, 32, 33] , which may be why patients with H1N1 ARDS have a higher ICU mortality rate (in the post-pandemic H1N1 infection period).

Secondly, a recent study showed that ECMO withdrawal failure was the sole factor associated with ICU mortality [34] . As a result, depending on the meta-analysis, a higher incidence of nosocomial pneumonia in the ECMO group may Systematic Review and Meta-Analysis of ECMO in ARDS lead to ECMO withdrawal failure, which then leads to higher ICU mortality. More bleeding complications in the ECMO group may also be a culprit. The present study concludes that patients in the ECMO group have higher SOFA and APACHE II scores when all studies with complete data were combined in the meta-analysis. This may also have occurred in the six included studies [21, 22, [25] [26] [27] 30] reporting ICU mortality, with bleeding complications leading to more sicker patients in the ECMO group, followed, as a consequence, by a higher ICU mortality.

In addition, some differences in management deserve attention, such as time to the initiation of ECMO, the application of steroids, and sample size. However, the included studies did not provide complete data for these factors, so it is regrettable that they could not be analysed with specific data, in order to draw conclusions.

Lastly, studies have found that hyperlactataemia before ECMO and higher dynamic driving pressure of patients needing ECMO in first 3 days were independent risk factors for increased ICU mortality [35, 36] . Nevertheless, haematological disease, early acute kidney injury, corticosteroid therapy, and early haemodynamic failure might all be associated with the higher mortality rate in H1N1 ARDS [37, 38] . Therefore, the influence factors in ICU mortality are numerous, and more rigorous studies are needed to confirm the relationship between ECMO support and the ICU mortality of patients with ARDS.

The meta-analysis included four RCTs and 14 RCS. The studies were mostly retrospective and had been published over a long period of time, during which ECMO technology and knowledge regarding the safety of mechanical ventilation changed greatly.

Furthermore, patients with ARDS receiving ECMO, whether as part of an RCT or RCS, were prone to having more serious conditions and higher disease scores (SOFA and APACHE II) (Figures 11 and 12 ). And as can be seen in Figures 2-12 , the results of the analysis id not change, even when RCSs were excluded from the sensitivity analysis. Of the four RCTs, two were published .20 years ago. Subgroup analysis showed that the results did not change after the removal of these two RCTs. Therefore, our conclusion is reliable.

Combined with the results of this paper and past studies [39] , it can be concluded that ECMO plays an important role in the treatment of ARDS and will certainly be included as a standard treatment in future guidelines. However, the factors influencing ECMO treatment have not been clearly stated.

Ultrasound is a convenient and commonly used monitor of the disease course, which is critical for lung assessment and to identify complications in the ICU early. Daily lung ultrasound assessment is recommended during ECMO treatment in patients with ARDS [40] . The lactate clearance within 72 hours of the initiation of ECMO may contribute to risk stratification and the mortality of patients with ARDS [41] . However, some studies do not support this conclusion [42, 43] . ECMOnet score [44] has long been concerned with predicting the efficacy of ECMO, and it is also used as a tool to evaluate the indications and time nodes of ECMO in ARDS. Research has found that, in general, obese (BMI .30 kg/m 2 ) patients with refractory ARDS are more likely to need ECMO treatment [45, 46] , but there is no evidence of the relation between obesity and higher mortality.

Right ventricular hypertrophy is a side effect of ECMO support, which may be attributed to increased afterload and higher BMI. Right ventricular hypertrophy also has a negative impact on ICU mortality [45] .

Firstly, many important variables influenced the results of the study, such as the duration of ECMO, the CMV settings, number of mechanical ventilation days, prone positioning before ECMO, different populations, and time to initiation of ECMO. With regard to the 14 observational studies included, this review cannot overcome the limitations of primary studies. Most of the studies included in this meta-analysis did not report data on these indicators in detail.

Secondly, even though higher disease severity scores (SOFA and APACHE II) were associated with ECMO treatment, each study outcome included different articles, and more detailed data are needed to see if outcomes are affected by disease severity scores.

The meta-analysis showed that ECMO was associated with reduced 60-day and 1-year mortality, but increased ICU mortality, compared to CMV in patients with ARDS. Extracorporeal Systematic Review and Meta-Analysis of ECMO in ARDS membrane oxygenation may have different effects on different types of ARDS, such as H1N1 ARDS. In the subgroup analysis, ECMO treatment increased ICU mortality and the incidence of nosocomial pneumonia in patients with H1N1 ARDS.

Extracorporeal membrane oxygenation can be used as a standard step in the management of ARDS. It should be used immediately when high-risk criteria are satisfied, rather than as a late-stage rescue therapy in end-stage ARDS or multiorgan failure.

However, the appropriate time at which to use ECMO, the best applicable population, the clinical characteristics of patients, evaluation of efficacy, the best way in which to reduce the complications of ECMO, and the ARDS pathogen type for the best treatment effect are all problems that need to be solved. Therefore, it is hoped that there will be more highquality research to address these issues.

We report no relevant funding sources associated with this manuscript.

There are no conflicts of interest to disclose.

J.W. was involved in the study design, data curation, formal analysis, investigation, methodology, project administration, resources, software, validation, visualisation, writing (original draft, final content, writing), and review and editing. Y.W. was involved with data curation, formal analysis, investigation, methodology, resources, validation, visualisation, writing (original draft). X.K.X. and T.W. carried out investigation and validation. G.Z. was involved in the study conceptualisation, project administration, software, supervision, visualisation, writing, review, and editing. All authors read and approved the manuscript.

Acute respiratory distress in adults

Definition and epidemiology of acute respiratory distress syndrome

Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis

Alcohol and lung injury and immunity

Incidence and outcomes of acute lung injury

Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in Intensive Care Units in 50 countries

Physical complications in acute lung injury survivors: a two-year longitudinal prospective study

Guidelines on the management of acute respiratory distress syndrome

High-frequency oscillation in early acute respiratory distress syndrome

Encou-RAGE-ing lung protection in patients with acute respiratory distress syndrome under extracorporeal membrane oxygenation

Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Acute respiratory distress syndrome: the Berlin Definition

An expanded definition of the adult respiratory distress syndrome

The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination

Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study

Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome

Acute respiratory distress syndrome with and without extracorporeal membrane oxygenation: a score matched study

Survival of patients with severe acute respiratory distress syndrome treated without extracorporeal membrane oxygenation

Quality of life and lung function in survivors of extracorporeal membrane oxygenation for acute respiratory distress syndrome

Controlled airway pressure therapy, nitric oxide inhalation, prone position, and extracorporeal membrane oxygenation (ECMO) as components of an integrated approach to ARDS

Extracorporeal lung support in H1N1 provoked acute respiratory failure: the experience of the German ARDS Network

Single-center experience with venovenous ECMO for influenza-related ARDS

Assessment of 1-year outcomes in survivors of severe acute respiratory distress syndrome receiving extracorporeal membrane oxygenation or mechanical ventilation: a prospective observational study

Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome

Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis

High survival rate in 122 ARDS patients managed according to a clinical algorithm including extracorporeal membrane oxygenation

Treatment of severe acute respiratory distress syndrome: role of extracorporeal gas exchange

Extracorporeal membrane oxygenation: a ten-year experience

Extracorporeal membrane oxygenation (ECMO) in adults with acute respiratory distress syndrome (ARDS): a 6-year experience and casecontrol study

Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1)

Influenza A (H1N1) vs non-H1N1 ARDS: analysis of clinical. course

Impact of obesity in patients infected with 2009 influenza A(H1N1)

The effect of an improvement of experience and training in extracorporeal membrane oxygenation management on clinical outcomes

Dynamic driving pressure associated mortality in acute respiratory distress syndrome with extracorporeal membrane oxygenation

Lactate and echocardiography before veno-venous extracorporeal membrane oxygenation support

Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients

Risk factors associated to noninvasive ventilation failure in primary influenza A pneumonia in the critical care setting

Extracorporeal membrane oxygenation for acute respiratory distress syndrome: EOLIA and beyond

Lung ultrasound for daily monitoring of ARDS patients on extracorporeal membrane oxygenation: preliminary experience

Serial lactate measurements as a prognostic tool in venovenous extracorporeal membrane oxygenation support

Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome: single-centre experience with 1-year follow-up

Restrictive transfusion practice during extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome

Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to influenza A (H1N1) pneumonia: the ECMOnet score

Body mass index and echocardiography in refractory ARDS treated with veno-venous extracorporeal membrane oxygenation

Does weight matter? Outcomes in adult patients on venovenous extracorporeal membrane oxygenation when stratified by obesity class

We would like to thank all those who have contributed to this article.